Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.


BACKGROUND Palliative treatment ore remains a significant clinical problem. OBJECTIVES To retrospectively determine the clinical response to 131I-MIBG therapy at low doses in patients with refractory neuroblastoma. METHODS We performed a retrospective chart review of 10 patients with neuroblastoma treated with 1311-MIBG at Rambam Health Care Campus from… (More)


  • Presentations referencing similar topics